AtriCure Inc. (ATRC) PT Raised to $91 at Needham & Company on FDA Approval
Tweet Send to a Friend
Needham & Company analyst Mike Matson raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $91.00 (from $81.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
